Recruiting Systemic Lupus Erythematosus Studies in Tucson
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult...
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population....
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer ar...
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC)...
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ...
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatm...
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk
The goal of this clinical trial is to learn if the culturally adapted couples sleep health intervention (Nuestro Sueno) improves positive airway pressure use and sleep among Hispanic couples in which ...
About Systemic Lupus Erythematosus Clinical Trials in Tucson
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect the joints, skin, kidneys, blood cells, brain, heart, and lungs. It is characterized by periods of flares and remission. Treatment includes antimalarials, immunosuppressants, corticosteroids, and biologics like belimumab.
There are currently 7 systemic lupus erythematosus clinical trials recruiting participants in Tucson, ARIZONA. These studies are seeking a combined 2,862 participants. Research is being sponsored by AbbVie, Bristol-Myers Squibb, Viatris Innovation GmbH and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Systemic Lupus Erythematosus Clinical Trials in Tucson — FAQ
Are there systemic lupus erythematosus clinical trials in Tucson?
Yes, there are 7 systemic lupus erythematosus clinical trials currently recruiting in Tucson, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Tucson?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.
Are clinical trials in Tucson free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.
What systemic lupus erythematosus treatments are being tested?
The 7 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for systemic lupus erythematosus.
Data updated March 2, 2026 from ClinicalTrials.gov